drugset / Trial / NCT03529942

Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee

NCT03529942

Phase 3 Completed 129 enrolled Pacira Pharmaceuticals, Inc
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label study assessing the effect of the administration of a single intra-articular (IA) injection of FX006 32 mg on synovial volume in patients with osteoarthritis (OA) of the knee.

Timeline

Start
2018-04-24
Primary completion
2019-11-08
Completion
2020-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Tafamidis Unknown 32 mg Other

Indications